

Terra L Lasho

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2545624/terra-l-lasho-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201
papers

3,164
citations

30
h-index

53
g-index

203
ext. papers

4,037
ext. citations

4.6
avg, IF

5.11
L-index

#	Paper	IF	Citations
201	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. <i>Blood</i> , 2014 , 124, 2507-13; quiz 2615	2.2	424
200	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018 , 36, 310-318	2.2	224
199	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. <i>Blood Advances</i> , 2016 , 1, 21-30	7.8	163
198	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. <i>American Journal of Hematology</i> , 2014 , 89, E121-4	7.1	145
197	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. <i>Blood</i> , 2012 , 120, 4168-71	2.2	128
196	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , 2018 , 32, 1631-1642	11.7	117
195	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. <i>Blood</i> , 2014 , 124, 2465-6	2.2	105
194	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. <i>Nature Medicine</i> , 2015 , 21, 1473-80	50.5	97
193	Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. <i>British Journal of Haematology</i> , 2006 , 135, 683-7	4.5	89
192	Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. <i>American Journal of Hematology</i> , 2016 , 91, 390-4	7.1	72
191	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. <i>Leukemia</i> , 2018 , 32, 1189-1199	10.7	65
190	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. <i>British Journal of Haematology</i> , 2020 , 189, 291-302	4.5	58
189	ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2015 , 90, 653-6	7.1	58
188	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. <i>American Journal of Hematology</i> , 2016 , 91, 492-8	7.1	55
187	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. <i>American Journal of Hematology</i> , 2018 , 93, 348-355	7.1	54
186	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 599-610	6.4	50
185	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. <i>American Journal of Hematology</i> , 2017 , 92, 1311-1317	7.1	50

184	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 56-61	7.1	48
183	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. <i>Leukemia</i> , 2018 , 32, 2274-2278	10.7	47
182	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. <i>American Journal of Hematology</i> , 2016 , 91, 888-93	7.1	47
181	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 542-548	7.1	41
180	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. <i>Leukemia</i> , 2020 , 34, 1407-1421	10.7	40
179	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. <i>Blood Advances</i> , 2018 , 2, 2964-2972	7.8	40
178	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. <i>American Journal of Hematology</i> , 2018 , 93, 65-73	7.1	37
177	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. <i>American Journal of Hematology</i> , 2016 , 91, 503-6	7.1	37
176	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1488-1493	1.9	35
175	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. <i>American Journal of Hematology</i> , 2018 , 93, 691-697	7.1	34
174	Monocytosis in polycythemia vera: Clinical and molecular correlates. <i>American Journal of Hematology</i> , 2017 , 92, 640-645	7.1	31
173	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018 , 93, 1474-1484	7.1	31
172	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. <i>Blood Cancer Journal</i> , 2018 , 8, 12	7	30
171	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. <i>Blood Cancer Journal</i> , 2019 , 9, 12	7	28
170	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. <i>American Journal of Hematology</i> , 2019 , 94, 767-779	7.1	27
169	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018 , 8, 29	7	27
168	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. <i>Leukemia</i> , 2018 , 32, 1254-1258	10.7	26
167	CALR mutation studies in chronic neutrophilic leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 450	7.1	26

166	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 835-838	4.5	23
165	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. <i>American Journal of Hematology</i> , 2017 , 92, E614-E618	7.1	20
164	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. <i>Leukemia</i> , 2018 , 32, 1850-1856	10.7	19
163	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. <i>British Journal of Haematology</i> , 2016 , 175, 534-536	4.5	19
162	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. <i>British Journal of Haematology</i> , 2018 , 182, 594-597	4.5	18
161	Mutations and karyotype predict treatment response in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, 1420-1426	7.1	18
160	Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. <i>American Journal of Hematology</i> , 2016 , 91, E12-4	7.1	17
159	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. <i>Blood Cancer Journal</i> , 2018 , 8, 21	7	17
158	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. <i>American Journal of Hematology</i> , 2018 , 93, 1461-1466	7.1	17
157	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFR mutation. <i>American Journal of Hematology</i> , 2016 , 91, E10-1	7.1	17
156	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. <i>Leukemia</i> , 2020 , 34, 656-661	10.7	17
155	JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. <i>American Journal of Hematology</i> , 2018 , 93, E93-E96	7.1	14
154	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1363-1374	6.4	14
153	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018 , 8, 82	7	14
152	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018 , 8, 18	7	13
151	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). <i>Blood Cancer Journal</i> , 2017 , 7, 658	7	13
150	MPL-mutated essential thrombocythemia: a morphologic reappraisal. <i>Blood Cancer Journal</i> , 2018 , 8, 1217		13
149	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021 , 12, 2901	17.4	12

148	Mayo CALR mutation type classification guide using alpha helix propensity. <i>American Journal of Hematology</i> , 2018 , 93, E128-E129	7.1	11
147	Concurrent activating KIT mutations in systemic mastocytosis. <i>British Journal of Haematology</i> , 2016 , 173, 153-6	4.5	11
146	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. <i>Leukemia</i> , 2020 , 34, 2519-2524	10.7	10
145	Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. <i>American Journal of Hematology</i> , 2013 , 88, 741-6	7.1	10
144	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. <i>Blood</i> , 2013 , 122, 662-662	2.2	10
143	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. <i>Annals of Hematology</i> , 2016 , 95, 1185-9	3	10
142	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 678-681	4.5	10
141	Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2020 , 33, 101171	4.2	9
140	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018 , 8, 32	7	9
139	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 354-354	2.2	9
138	Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 450-459	3.1	9
137	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. <i>Blood Cancer Journal</i> , 2019 , 9, 11	7	8
136	Mutations and thrombosis in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021 , 11, 77	7	8
135	Special considerations in the management of patients with myelodysplastic syndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. <i>American Journal of Hematology</i> , 2020 , 95, E203-E208	7.1	7
134	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. <i>American Journal of Hematology</i> , 2018 , 93, E146-E148	7.1	7
133	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, E235-E238	7.1	7
132	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. <i>American Journal of Hematology</i> , 2018 , 93, 1347-1357	7.1	7
131	Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 460-464	3.1	7

130	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. <i>Leukemia</i> , 2021 , 35, 644-649	10.7	6
129	World Health Organization class-independent risk categorization in mastocytosis. <i>Blood Cancer Journal</i> , 2019 , 9, 29	7	5
128	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2998-3001	1.9	5
127	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). <i>Blood</i> , 2018 , 132, 578-578	2.2	5
126	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. <i>Blood Advances</i> , 2020 , 4, 5716-5721	7.8	5
125	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2019 , 94, 299-305	7.1	5
124	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>American Journal of Hematology</i> , 2019 , 94, E231-E234	7.1	4
123	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>British Journal of Haematology</i> , 2020 , 189, e104-e108	4.5	4
122	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2010 , 116, 3070-3070	2.2	4
121	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016 , 128, 1123-1123	2.2	4
120	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. <i>Blood</i> , 2016 , 128, 4320-4320	2.2	4
119	AKT activation is a feature of CALR mutant myeloproliferative neoplasms. <i>Leukemia</i> , 2019 , 33, 271-274	10.7	3
118	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. <i>Blood</i> , 2006 , 108, 2680-2680	2.2	3
117	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , 2013 , 122, 104-104	2.2	3
116	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. <i>Blood</i> , 2015 , 126, 55-55	2.2	3
115	Atypical CML- the role of morphology and precision genomics. <i>Best Practice and Research in Clinical Haematology</i> , 2020 , 33, 101133	4.2	3
114	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. <i>American Journal of Hematology</i> , 2019 , 94, 286-290	7.1	3
113	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <i>Blood Cancer Journal</i> , 2018 , 8, 118	7	3

112	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. <i>American Journal of Hematology</i> , 2020 , 95, E86-E89	7.1	2
111	Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms. <i>Blood</i> , 2020 , 136, 1-1	2.2	2
110	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. <i>Blood</i> , 2010 , 116, 4112-4112	2.2	2
109	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2867-2867	2.2	2
108	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. <i>Blood</i> , 2013 , 122, 1510-1510	2.2	2
107	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. <i>Blood</i> , 2015 , 126, 828-828	2.2	2
106	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. <i>Blood</i> , 2016 , 128, 4247-4247	2.2	2
105	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4249-4249	2.2	2
104	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021 , 96, E327-E330	7.1	2
103	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. <i>Leukemia</i> , 2019 , 33, 780-785	10.7	2
102	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. <i>American Journal of Hematology</i> , 2021 , 96, E157-E162	7.1	2
101	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. <i>American Journal of Hematology</i> , 2018 , 93, E383-E386	7.1	2
100	Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms. <i>American Journal of Hematology</i> , 2021 , 96, E392-E396	7.1	2
99	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E164-E167	7.1	1
98	ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility. <i>Blood</i> , 2020 , 136, 27-28	2.2	1
97	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 26	7	1
96	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. <i>Haematologica</i> , 2022 ,	6.6	1
95	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018 , 132, 3035-3035	2.2	1

94	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. <i>Blood</i> , 2018 , 132, 3040-3040	2.2	1
93	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 3003-3003	2.2	1
92	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. <i>Blood</i> , 2010 , 116, 3068-3068	2.2	1
91	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. <i>Blood</i> , 2010 , 116, 4105-4105	2.2	1
90	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. <i>Blood</i> , 2011 , 118, 3850-3850	2.2	1
89	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. <i>Blood</i> , 2012 , 120, 2836-2836	2.2	1
88	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. <i>Blood</i> , 2013 , 122, 109-109	2.2	1
87	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. <i>Blood</i> , 2013 , 122, 2830-2830	2.2	1
86	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. <i>Blood</i> , 2015 , 126, 1599-1599	2.2	1
85	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. <i>Blood</i> , 2015 , 126, 2801-2801	2.2	1
84	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. <i>Blood</i> , 2015 , 126, 350-350	2.2	1
83	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4248-4248	2.2	1
82	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. <i>Blood</i> , 2016 , 128, 4343-4343	2.2	1
81	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. <i>Blood</i> , 2016 , 128, 948-948	2.2	1
80	Asxl1 loss cooperates with oncogenic Nras in mice to reprogram immune microenvironment and drive leukemic transformation. <i>Blood</i> , 2021 ,	2.2	1
79	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019 , 134, 4182-4182	2.2	1
78	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 925-925	2.2	1
77	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. <i>American Journal of Hematology</i> , 2020 , 95, E31-E34	7.1	1

76	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 54	7	1
75	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. <i>Leukemia</i> , 2021 , 35, 3329-3333	10.7	1
74	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021 , 96, 1450-1460	7.1	1
73	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. <i>Blood</i> , 2018 , 132, 4301-4301	2.2	0
72	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. <i>Blood</i> , 2011 , 118, 460-460	2.2	0
71	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. <i>Blood</i> , 2016 , 128, 1987-1987	2.2	0
70	Genetic predictors of response to specific drugs in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018 , 8, 120	7	0
69	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2021 , 1-6	1.9	0
68	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. <i>Leukemia Research</i> , 2022 , 106818	2.7	0
67	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. <i>Nature Communications</i> , 2022 , 13, 1434	17.4	0
66	Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2020 , 136, 31-32	2.2	
65	Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model. <i>Blood</i> , 2020 , 136, 10-11	2.2	
64	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. <i>Blood</i> , 2020 , 136, 34-35	2.2	
63	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020 , 136, 35-36	2.2	
62	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2021 , 138, 2592-2592	2.2	
61	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2021 , 138, 3684-3684	2.2	
60	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2021 , 138, 1470-1470	2.2	
59	Tumor Mutational Burden in Histiocytic Neoplasms. <i>Blood</i> , 2021 , 138, 3634-3634	2.2	

58	Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project. <i>Blood</i> , 2021 , 138, 2164-2164	2.2
57	Cytogenetic Profile, JAK2V617F Mutational Status, and Response to Drug Therapy in Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2005 , 106, 2591-2591	2.2
56	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. <i>Blood</i> , 2006 , 108, 116-116	2.2
55	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. <i>Blood</i> , 2006 , 108, 661-661	2.2
54	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.. <i>Blood</i> , 2007 , 110, 3555-3555	2.2
53	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. <i>Blood</i> , 2007 , 110, 676-676	2.2
52	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. <i>Blood</i> , 2007 , 110, 2550-2550	2.2
51	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. <i>Blood</i> , 2007 , 110, 3191-3191	2.2
50	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 4300-4300	2.2
49	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. <i>Blood</i> , 2018 , 132, 3034-3034	2.2
48	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. <i>Blood</i> , 2018 , 132, 1761-1761	2.2
47	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. <i>Blood</i> , 2018 , 132, 582-582	2.2
46	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. <i>Blood</i> , 2018 , 132, 1767-1767	2.2
45	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018 , 132, 4344-4344	2.2
44	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. <i>Blood</i> , 2018 , 132, 3050-3050	2.2
43	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018 , 132, 3033-3033	2.2
42	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. <i>Blood</i> , 2018 , 132, 4291-4291	2.2
41	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. <i>Blood</i> , 2018 , 132, 3036-3036	2.2

40	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. <i>Blood</i> , 2018 , 132, 3100-3100	2.2
39	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018 , 132, 3044-3044	2.2
38	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. <i>Blood</i> , 2018 , 132, 1771-1771	2.2
37	Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019 , 134, 4232-4232	2.2
36	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019 , 134, 3005-3005	2.2
35	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019 , 134, 2981-2981	2.2
34	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 1697-1697	2.2
33	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019 , 134, 1710-1710	2.2
32	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). <i>Blood</i> , 2015 , 126, 4067-4067	2.2
31	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015 , 126, 4062-4062	2.2
30	Molecular Correlates of Anemia in Primary Myelofibrosis. <i>Blood</i> , 2015 , 126, 4068-4068	2.2
29	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2015 , 126, 2864-2864	2.2
28	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. <i>Blood</i> , 2015 , 126, 2882-2882	2.2
27	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. <i>Blood</i> , 2016 , 128, 4259-4259	2.2
26	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016 , 128, 110-110	2.2
25	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. <i>Blood</i> , 2016 , 128, 1986-1986	2.2
24	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016 , 128, 1988-1988	2.2
23	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016 , 128, 1989-1989	2.2

22	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. <i>Blood</i> , 2016 , 128, 3111-3111	2.2
21	Revisiting Mastocytosis in Adults: A Mayo Clinic Case Series of 342 Patients Including Information on KITD816V and JAK2V617F.. <i>Blood</i> , 2008 , 112, 1757-1757	2.2
20	Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders.. <i>Blood</i> , 2008 , 112, 3371-3371	2.2
19	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 4009-4009	2.2
18	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. <i>Blood</i> , 2011 , 118, 3795-3795	2.2
17	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. <i>Blood</i> , 2011 , 118, 3803-3803	2.2
16	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 5158-5158	2.2
15	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011 , 118, 1756-1756	2.2
14	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. <i>Blood</i> , 2011 , 118, 971-971	2.2
13	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. <i>Blood</i> , 2011 , 118, 5154-5154	2.2
12	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. <i>Blood</i> , 2011 , 118, 2807-2807	2.2
11	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. <i>Blood</i> , 2011 , 118, 1751-1751	2.2
10	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. <i>Blood</i> , 2012 , 120, 1751-1751	2.2
9	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. <i>Blood</i> , 2012 , 120, 1711-1711	2.2
8	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥1% Ring Sideroblasts.. <i>Blood</i> , 2012 , 120, 2803-2803	2.2
7	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. <i>Blood</i> , 2012 , 120, 430-430	2.2
6	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2831-2831	2.2
5	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. <i>Blood</i> , 2013 , 122, 1587-1587	2.2

- | | | |
|---|---|-----|
| 4 | U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. <i>Blood</i> , 2013 , 122, 4060-4060 | 2.2 |
| 3 | Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013 , 122, 4048-4048 | 2.2 |
| 2 | Novel therapeutic targets for chronic myelomonocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021 , 34, 101244 | 4.2 |
| 1 | Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. <i>Leukemia Research</i> , 2019 , 87, 106264 | 2.7 |